Literature DB >> 15004326

A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations.

Wieslaw K Dowjat1, Izabela Kuchna, Thomas Wisniewski, Jerzy Wegiel.   

Abstract

A novel presenilin-1 (PS1) mutation (P117S) in an American pedigree is described. We compare clinical, neuropathological and cell culture phenotypes produced by this mutation with another codon 117 mutation that was earlier discovered by our group in a Polish kindred. Both mutations are associated with an unusually severe Alzheimer disease (AD) phenotype, with the onset starting before the third decade of life, rapid disease progression and acute presentation of clinical symptoms. The severity of clinical phenotype was closely correlated with the abundance of pathology: massive deposition of Abeta42 in plaques, severe neurofibrillary degeneration and neuronal loss. When overexpressed in mouse neuroblastoma N2a cells, both mutations caused loss of an ability to promote neurite outgrowth and produced an increase in the ratio of secreted Abeta42/40 amyloid peptides. In stably transfected N2a cell lines only mutant proteins were endoproteolytically cleaved indicating some dependability of this process on the presence of mutation. Taken together, our results show that clinical and cell culture phenotypes produced by these 2 codon 117 mutations are closely related suggesting that the pathogenic action of PS1 may involve effect on neurite outgrowth and endoproteolytic cleavage of the full-length protein. Given the high potency in vivo and in vitro of both codon 117 mutations, this site of PS1 must be particularly important for its normal/pathogenic function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004326     DOI: 10.3233/jad-2004-6105

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

Review 1.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

2.  Novel presenilin 1 variant (P117A) causing Alzheimer's disease in the fourth decade of life.

Authors:  John S K Kauwe; Jun Wang; Sumi Chakraverty; Alison M Goate; Andres F Henao-Martinez
Journal:  Neurosci Lett       Date:  2008-04-15       Impact factor: 3.046

3.  Difficult case of a rare form of familial Alzheimer's disease with PSEN1 P117L mutation.

Authors:  Ana Luísa Rocha; Andreia Costa; Maria Carolina Garrett; Joana Meireles
Journal:  BMJ Case Rep       Date:  2018-12-13

4.  Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes.

Authors:  Matthias Cacquevel; Lorène Aeschbach; Jemila Houacine; Patrick C Fraering
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

5.  The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease.

Authors:  Alessandro Padovani; Nicola Gilberti; Barbara Borroni
Journal:  Int J Alzheimers Dis       Date:  2011-02-21

Review 6.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.

Authors:  A J Larner; M Doran
Journal:  J Neurol       Date:  2005-11-04       Impact factor: 6.682

Review 7.  The genetics of Alzheimer's disease.

Authors:  Eva Bagyinszky; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Clin Interv Aging       Date:  2014-04-01       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.